Abstract：
UNASSIGNED: The Rho kinase inhibitor netarsudil is a recently approved therapeutic option for the management of increased intraocular pressure in the United States. Although phase 3 clinical trials noted corneal changes related to the medication-namely, nonvisually-significant corneal verticillata-descriptions of a unique form of cystic epithelial edema began to surface as netarsudil (and its sister drug ripasudil, approved in Japan) gained widespread use. This series adds 3 new cases and reviews the current literature on this unique side effect.
摘要：
未经批准：Rho激酶抑制剂netarsudil是美国最近批准的治疗眼内压升高的治疗选择。虽然3期临床试验注意到与药物相关的角膜变化-即，视觉上无意义的角膜斜视-对囊性上皮水肿的独特形式的描述开始显现为netarsudil（及其姐妹药物ripasudil，在日本批准)获得广泛使用。本系列增加了3个新病例，并回顾了目前关于这种独特副作用的文献。
